ArticleTherapeutic advances in gastroenterology2013
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
Article in Therapeutic advances in gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Pooled it
- RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.Biomarkers in medicine · 2017Pooled it
- Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.Journal of cancer research and clinical oncology · 2018Trial
- Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer.Journal of translational medicine · 2016Trial
- Targeted Therapy and Personalized Medicine.Cancer treatment and research · 2023Article
- Article
- Analysis of the Relationship between the Expression Level of TTR and APOH and Prognosis in Patients with Colorectal Cancer Metastasis Based on Bioinformatics.Contrast media & molecular imaging · 2022Article
- Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- A Systematic Literature Review and Meta-Analysis Describing the Prevalence ofGastroenterology research · 2020Article
- A National Survey of Medical Oncologist's Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab.Dermatology and therapy · 2019Article
- Microsatellite instability and manifestations of angiogenesis in stage IV of sporadic colorectal carcinoma.Medicine · 2019Observational
- Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Article
- Molecular predictive markers in tumors of the gastrointestinal tract.World journal of gastrointestinal oncology · 2016Review
- Article
- The focus on sample quality: Influence of colon tissue collection on reliability of qPCR data.Scientific reports · 2016Article
- Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.PloS one · 2016Article
- A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.Journal of clinical pathology · 2015Article
- Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.Journal of clinical pathology · 2014Observational
- Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.Cancer biology & therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in the treatment of metastatic colorectal cancer have led to an improvement in survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is partly as a result of the addition of irinotecan and oxaliplatin, but is also due to the use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) and antiangiogenic drugs such as bevacizumab. However, there are significant molecular differences between tumours which can affect both prognosis and response to treatment. Personalized medicine aims to tailor treatment according to the characteristics of the individual patient and is now a clinical reality as testing for KRAS mutations to guide treatment with the anti-EGFR monoclonal antibodies cetuximab and panitumumab is now part of routine clinical practice. However, not all patients who are KRAS wild type respond to anti-EGFR therapy and a validated biomarker for antiangiogenic therapy is still lacking. Therefore, other biomarkers are needed to assist with predicting response to both existing drugs as well as to drugs currently under investigation. This review summarizes the molecular biology of colorectal cancer, focusing on the genetic features that are currently most clinically relevant. Current and emerging biomarkers are reviewed along with their roles in selecting patients for targeted treatment with currently licensed therapies and drugs being evaluated in clinical trials. The value of predictive biomarkers of chemosensitivity and potential future treatment strategies are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.